Sera Prognostics (NASDAQ:SERA) CEO Zhenya Lindgardt Sells 22,639 Shares of Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 22,639 shares of the stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $1.90, for a total value of $43,014.10. Following the transaction, the chief executive officer owned 741,287 shares of the company’s stock, valued at $1,408,445.30. The trade was a 2.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Zhenya Lindgardt also recently made the following trade(s):

• On Wednesday, March 11th, Zhenya Lindgardt sold 2,973 shares of Sera Prognostics stock. The shares were sold at an average price of $2.04, for a total transaction of $6,064.92.

Sera Prognostics Price Performance

Shares of SERA traded up $0.11 during trading hours on Friday, hitting $2.10. The company’s stock had a trading volume of 21,410 shares, compared to its average volume of 56,810. The business has a 50 day simple moving average of $2.76 and a two-hundred day simple moving average of $3.05. Sera Prognostics, Inc. has a 52-week low of $1.37 and a 52-week high of $4.20. The company has a market cap of $81.20 million, a price-to-earnings ratio of -2.72 and a beta of 1.01.

Sera Prognostics News Roundup

Here are the key news stories impacting Sera Prognostics this week:

• Neutral Sentiment: Coverage piece contrasting Sera and Revvity — a recent article compares SERA to Revvity (RVTY), which may influence investor attention or comparisons across healthcare peers but contains no company-specific fundamental disclosure. Contrasting Sera Prognostics (NASDAQ:SERA) and Revvity (NYSE:RVTY)
• Negative Sentiment: CEO Zhenya Lindgardt sold a total of 25,612 shares across filings (22,639 shares at $1.90 on Mar 10 and 2,973 shares at $2.04 on Mar 11), raising roughly $49k; the filings show a near 3% and 0.4% reduction in holdings respectively. Significant CEO selling can weigh on sentiment for a small-cap biotech. SEC Filing – Lindgardt Sales
• Negative Sentiment: CFO Austin Aerts sold 7,088 shares across two trades (6,069 at $1.90 and 1,019 at $2.04), totaling roughly $13.6k and reducing his stake ~2.2% and 0.38% in filings. Insider sales by senior finance officers can signal near-term liquidity-taking and may be viewed unfavorably in thinly traded names. SEC Filing – Aerts Sales
• Negative Sentiment: Other insiders (General Counsel Benjamin Jackson; John J. Boniface; Paul Kearney; Robert Gardner Harrison) executed small sales on Mar 11 (combined ~4,656 shares, ~ $9.5k). While each sale is modest, the broad pattern of multiple insiders selling within a short window can amplify investor concern about management conviction. SEC filings: Jackson Jackson Filing, Boniface Boniface Filing, Kearney Kearney Filing, Harrison Harrison Filing

Hedge Funds Weigh In On Sera Prognostics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SERA. Wealth Enhancement Advisory Services LLC bought a new stake in Sera Prognostics in the 4th quarter worth approximately $31,000. Riverview Capital Advisers LLC purchased a new position in shares of Sera Prognostics during the second quarter worth approximately $35,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Sera Prognostics in the 3rd quarter worth approximately $38,000. Lido Advisors LLC bought a new stake in shares of Sera Prognostics in the 3rd quarter worth approximately $68,000. Finally, Cetera Investment Advisers purchased a new stake in shares of Sera Prognostics in the 4th quarter valued at $74,000. 54.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

SERA has been the subject of a number of recent analyst reports. Jefferies Financial Group raised Sera Prognostics to a “strong-buy” rating in a report on Monday, December 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sera Prognostics in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $5.00.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.